Inclusion criteria
tumor, melanoma, squamous cell head and neck cancer, ICH, platinum-sensitive disease, Stage IIIB, squamous, adenosquamous, death, toxicity, NSCLC, esophageal cancer, squamous and adenocarcinoma, anaplastic lymphoma, adenocarcinoma, primary tumor, urothelial cancer, cancers, MRCLS, PD, tumors
OVARIAN CANCER, CANCERS, TUMOR, MELANOMA, OESOPHAGEAL CANCER, PRIMARY TUMOR, DISEASE, RECURRENT DISEASE, MUTANT, ADENOCARCINOMA, NSCLC, SQUAMOUS CELL CARCINOMA, TUMORS, LARGE CELL CARCINOMA, GASTRIC CANCER
Patients must have voluntarily agreed to participate by giving written informed consent in accordance with International Council on Harmonization (ICH) Good Clinical Practice (GCP) guidelines and applicable local regulations. Patients must have agreed to abide by all protocol-required procedures, including study-related assessments and management by the treating institution for the duration of the study and LTFU phase. Patients were ≥18 years to ≤75 years of age at the time of signing the study informed consent.Patients must have had histologically confirmed diagnosis of any one of the following cancers: (1) urothelial cancer (transitional cell cancer of the bladder, ureter, urethra or renal pelvis); (2) melanoma; (3) squamous cell carcinoma of the head and neck; (4) ovarian cancer; (5) NSCLC (squamous, adenosquamous, adenocarcinoma or large cell); (6) esophageal cancer (squamous and adenocarcinoma); (7) gastric cancer; (8) SS; or (9) MRCLS. Patients must have had measurable disease according to RECIST version 1.1 criteria before LD. Measurable disease was not required before leukapheresis. Patients must have had the following disease-specific requirements for their tumor type (note: there was no limit to the number of therapies before study entry). (1) Inoperable or metastatic (advanced) urothelial cancer: patients must have received at least one prior systemic therapy in the adjuvant or metastatic setting; may have received treatment with a programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. (2) Inoperable or metastatic (advanced) melanoma: patients must have received, were intolerant to or refused a cytotoxic T lymphocyte-associated protein 4 inhibitor (ipilimumab) or a PD-1 inhibitor (nivolumab or pembrolizumab) as monotherapy or a combination of ipilumumab and nivolumab. Patients must have received or were intolerant to a B-Raf proto-oncogene (BRAF) inhibitor or the combination of BRAF and mitogen-activated protein kinase inhibitors for BRAF(V600) mutant melanoma. (3) Inoperable or metastatic (advanced) squamous cell head and neck cancer: patients must have received a platinum-containing chemotherapy for treatment of primary tumor in adjuvant, locally advanced or metastatic settings, were intolerant to or refused such treatment. They may have received prior immunotherapy. (4) Inoperable or metastatic (advanced) ovarian, primary peritoneal or fallopian tube carcinoma: patients must have received platinum-containing chemotherapy and had platinum-refractory or platinum-resistant disease. If platinum-sensitive disease, patients should have received at least two lines of chemotherapy. Patients may have received poly (adenosine diphosphate-ribose) polymerase inhibitors, bevacizumab or immunotherapy. (5) Histologically or cytologically confirmed diagnosis of advanced NSCLC (Stage IIIB or Stage IV) or recurrent disease (squamous, adenosquamous, adenocarcinoma or large cell carcinoma): patients whose tumors were known to have epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) gene rearrangements must have failed (PD or unacceptable toxicity) prior EGFR inhibitor or ALK tyrosine kinase inhibitor, respectively. Patients with ROS-1Patients were HLA-A*02